Clareo Health | An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
Patients who sign the written informed consent to participate in the study.
Men or women aged ≥18 years.
Patients with CKD associated with type 2 diabetes and albuminuria (UACR \>30 mg/g).
Patients initiated on finerenone in routine clinical practice, according to the Summary of Product Characteristics (SmPC), within the 2 months prior to inclusion.
You may not be if
eGFR \< 25 mL/min/1.73 m².
Severe hepatic impairment.
Clinical diagnosis of chronic heart failure with reduced ejection fraction (HFrEF) and persistent symptoms.
Uncontrolled arterial hypertension (mean sitting systolic blood pressure \[SBP\] ≥160 mmHg or diastolic blood pressure \[DBP\] ≥100 mmHg at inclusion).
Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or a potassium-sparing diuretic that has not been discontinued at least 4 weeks prior to inclusion.
